R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
Roni Tamari,Franck Rapaport,Nan Zhang,Caroline J McNamara,Andrew T. Kuykendall,David A. Sallman,Rami S. Komrokji,Andrea Arruda,Vesna Najfeld,Lonette Sandy,Juan Medina,Rivka Litvin,Christopher Famulare,Minal Patel,Molly Maloy,Hugo Castro-Malaspina,Sergio Giralt,Rona Singer Weinberg,John Mascarenhas,Ruben A. Mesa,Damiano Rondelli,Amylou C. Dueck,Ross L. Levine,Vikas Gupta,Ronald Hoffman,Raajit K. Rampal +25 more
TL;DR: High-throughput sequencing of 585 genes on pre-transplant samples from 101 patients with myelofibrosis who underwent allo-HCT identifies genetic biomarkers in conjunction with clinical variables that may have important utility in guiding transplantation decision making.
Journal ArticleDOI
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl
John Mascarenhas,Ronald Hoffman,Moshe Talpaz,Aaron T. Gerds,Brady L. Stein,Vikas Gupta,Anita Szoke,Mark Drummond,Alexander Pristupa,Tanya Granston,Robert N. Daly,James P. Dean,Suliman Al-Fayoumi,Jennifer A. Callahan,Jack W. Singer,Jason Gotlib,Catriona Jamieson,Claire N. Harrison,Ruben A. Mesa,Srdan Verstovsek +19 more
TL;DR: PAC BID maintained this survival advantage vs BAT across nearly all demographic and MF-associated risk factors and population PK analyses showed that the steady-state plasma levels achieved with BID were higher than with QD, however the Cmax levels were lower.
Journal ArticleDOI
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Chad Cherington,James L. Slack,Jose F. Leis,Roberta H. Adams,Craig B. Reeder,Joseph R. Mikhael,John K. Camoriano,Pierre Noel,Veena Fauble,Jeffrey Betcher,Meagan S. Higgins,Ginger Gillette-Kent,Lisa D. Tremblay,Mary E Peterson,Jane Olsen,Raoul Tibes,Ruben A. Mesa +16 more
TL;DR: It is concluded that MPN-BP can be cured by allo-SCT in a significant percentage of patients, but that adequate leukemic clearance prior to allo -SCT offers an optimal outcome.
Journal ArticleDOI
Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research.
Jennifer Huberty,Ryan Eckert,Amylou C. Dueck,Heidi E. Kosiorek,Linda Larkey,Krisstina Gowin,Ruben A. Mesa +6 more
TL;DR: Online yoga demonstrated small effects on sleep, pain, and anxiety as well as a moderate effect on depression and remote blood draw procedures are feasible and the effect size of the intervention on TNF-α was large.
Journal ArticleDOI
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Shireen Sirhan,Terra L. Lasho,Curtis A. Hanson,Ruben A. Mesa,Animesh Pardanani,Ayalew Tefferi +5 more
TL;DR: It is suggested that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV.